Assessment based on a broad range of evidence
Members of the SMC committee consider a broad range of evidence when deciding which medicines should be approved for use by NHS Scotland. Decisions are made from a broad perspective by including wide mixture of backgrounds among committee members, from clinicians – most of whom have a direct role in patient care – to three volunteer public partners, who ensure the views of the Scottish public are represented.2
SUMMARY OF RECOMMENDATIONS FOR DYMISTA®2
Indication under review: for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
For patients in whom the combination of azelastine hydrochloride and fluticasone propionate nasal spray is an appropriate choice of therapy, Dymista® provides the two ingredients in a single nasal spray.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of Dymista®. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.